Buckman Co. v. Plaintiffs' Legal Committee
The Supreme Court ruled that people injured by defective spinal bone screws cannot sue a regulatory consulting company under state fraud law for allegedly lying to the FDA during the approval process, because federal law controls how fraud against the FDA is policed.
The decision means that claims accusing companies of deceiving the FDA to get medical devices approved must be pursued, if at all, through federal enforcement rather than lawsuits under the fifty different states' tort laws.
“Policing fraud against federal agencies is hardly "a field which the States have traditionally occupied,"”
Explaining why no presumption against federal preemption applied to fraud claims against the FDA.
How it got here: A federal trial court dismissed the fraud claims as preempted; the Third Circuit reversed; the Supreme Court agreed to hear the case to resolve a circuit split.
The Case in Depth
What happened
Patients who had orthopedic bone screws implanted in their spines sued Buckman, a consulting company that helped the screws' manufacturer, AcroMed, get the devices cleared by the FDA. The patients claimed Buckman made fraudulent statements to the FDA about the screws' intended use, and that without those lies the FDA would never have cleared the devices, so the patients would never have been injured. They sought damages under state tort law.
The question before the Court
Could people hurt by defective medical devices sue a regulatory consultant under state law for allegedly lying to the FDA to get the devices approved?
The Court's answer
No — the Court ruled that federal law preempts state-law fraud claims that exist only because a company allegedly deceived the FDA during the device-approval process. The FDA has its own extensive toolkit for investigating and punishing fraud against it, including injunctions, penalties, seizures, and criminal prosecution, and Congress gave enforcement power exclusively to the federal government. Letting fifty states' tort laws police fraud on the FDA would risk upsetting the careful, flexible balance the FDA strikes between approving devices quickly and ensuring their safety.
The Court distinguished this from ordinary state-law claims — like a straightforward negligence suit over a defective product — that don't depend entirely on an alleged violation of federal disclosure duties. Because these plaintiffs' claims existed solely by virtue of the federal approval scheme, allowing them to proceed under state law would interfere with the scheme Congress set up, so the claims could not go forward.
Curious how the Court got there? See the step-by-step legal reasoning →
Why it matters
Patients injured by medical devices lose one potential legal route: suing device makers or their consultants for tricking the FDA into approving a product. Device manufacturers and consulting firms gain protection from a patchwork of state lawsuits over their FDA submissions, leaving policing of such fraud entirely to the federal government.
What changes now
The Third Circuit's ruling allowing the fraud claims to proceed is reversed, and the fraud-on-the-FDA claims are barred. The Court left open whether such claims would also be subject to a separate express-preemption provision in the statute, since it did not need to reach that question. Enforcement of fraud against the FDA remains solely a matter for the federal government going forward.
What this does not decide
The Court did not decide whether these claims would also be expressly preempted under a different statutory provision, since it resolved the case on implied conflict-preemption grounds alone. It also did not address ordinary state-law claims, like the negligence claim in Medtronic v. Lohr, that don't depend solely on violations of FDA disclosure requirements.
Concurrences and dissents
Concurrence — Justice Stevens
“I do not believe the reasons advanced in the Court's opinion support the conclusion that Congress intended such a harsh result.”Stevens's concern that the majority's rule leaves fraud victims with no remedy at all.
Justice Stevens agreed the case should not proceed but for a narrower reason: the plaintiffs could not prove that, but for the alleged fraud, the FDA would have kept the device off the market, since the FDA still had not removed it despite knowing of the fraud allegations. He worried the majority's broad preemption rule would leave people harmed by agency fraud with no remedy at all, even where recognizing one would not interfere with FDA operations, and declined to join the Court's opinion on that basis.
How the Court got there
The legal reasoning, step by step
- The Court asked whether a presumption against federal preemption applied, since federal law normally leaves room for state regulation in fields states have traditionally handled. It found that policing fraud against a federal agency is not such a traditionally state-run field, so no presumption against preemption applied here.
- The Court then applied conflict preemption, the principle that state law is preempted when it stands as an obstacle to a comprehensive federal scheme, even without an express statute barring the state claims.
- The Court found that the federal Food, Drug, and Cosmetic Act and its Medical Device Amendments give the FDA an extensive, flexible toolkit — investigations, injunctions, civil penalties, seizures, and criminal prosecution — to detect and punish fraud in device applications, reflecting a deliberate federal balance between speed and safety in approving devices.
- The Court reasoned that letting state fraud-on-the-FDA lawsuits proceed would upset that balance: companies would either avoid seeking approval for beneficial but riskier uses out of fear of liability, or would flood the FDA with excess paperwork to protect against later second-guessing in state courts, slowing down the approval process the FDA controls.
- The Court distinguished this case from Silkwood v. Kerr-McGee Corp. (a 1984 case allowing certain state damages suits despite federal regulation), noting that the claims here exist solely because of the federal disclosure requirements, unlike the traditional tort duties at issue in Silkwood.
- Because the fraud claims depend entirely on the existence of the federal approval scheme rather than on independent state-law duties, the Court concluded that allowing them would exert an improper pull on Congress's regulatory scheme and are therefore preempted.
Doctrinal impact
Cases affected by this decision
Distinguishes Silkwood v. Kerr-McGee Corp. (464 U. S. 238)
Says Silkwood's traditional tort claim differs from fraud claims that exist only because of federal disclosure rules.
Distinguishes Medtronic, Inc. v. Lohr (518 U. S. 470)
Clarifies that Medtronic's negligence claim arose from a manufacturer's own failure of care, not solely from violating FDA rules.
Reaffirms Geier v. American Honda Motor Co. (529 U. S. 861)
Relies on Geier's rule that ordinary conflict preemption applies even with an express preemption clause.